Pathogenesis and control of chronic infections, Inserm, Etablissement Français du Sang, University of Montpellier, Montpellier, France.
Hai Phong University of Medicine and Pharmacy, Faculty of Public Health, Hai Phong, Vietnam.
Sci Rep. 2020 Apr 24;10(1):6999. doi: 10.1038/s41598-020-63990-w.
In Vietnam, harm reduction programs to control HIV among people who inject drugs (PWID) were implemented approximately 10 years ago. Since then, the HIV prevalence has declined in this population, however, the impact of these programs on the rate of new HIV and Hepatitis C (HCV) infections remains unknown as high mortality can exceed the rate of new infections. We evaluated HIV and HCV incidences in a cohort of active PWID in HaiPhong in 2014, who were recruited from a community-based respondent driven sampling (RDS) survey and followed for 1 year. Only HIV-negative or HCV-negative participants not on medication assisted treatment (MAT) were eligible. HIV/HCV serology was tested at enrollment and at 32- and 64-week follow-up visits. Among 603 RDS participants, 250 were enrolled in the cohort, including 199 HIV seronegative and 99 HCV seronegative PWID. No HIV seroconversion was reported during the 206 person-years (PY) of follow-up (HIV incidence of 0/100PY, one-sided 97.5%CI:0-1.8/100 PY). Eighteen HCV seroconversions were reported for an incidence of 19.4/100 PY (95%CI;11.5-30.7). In multivariate analysis, "Injecting more than twice daily" was associated with HCV seroconversion with an adjusted odds ratio of 5.8 (95%CI;1.8-18.1). In Hai Phong, in a context that demonstrates the effectiveness of HIV control programs, the HCV incidence remains high. New strategies such as mass access to HCV treatment should be evaluated in order to tackle HCV transmission among PWID.
在越南,大约 10 年前就开始实施针对注射吸毒者(PWID)的艾滋病毒减少伤害计划。此后,该人群中的艾滋病毒流行率有所下降,但这些计划对新的艾滋病毒和丙型肝炎(HCV)感染率的影响尚不清楚,因为高死亡率可能超过新感染率。我们评估了 2014 年在海防的一个活跃 PWID 队列中的 HIV 和 HCV 发病率,这些参与者是从基于社区的应答驱动抽样(RDS)调查中招募的,并随访了 1 年。只有 HIV 阴性或 HCV 阴性且未接受药物辅助治疗(MAT)的参与者符合条件。在入组时和 32 周和 64 周的随访时进行 HIV/HCV 血清学检测。在 603 名 RDS 参与者中,有 250 名参加了队列,包括 199 名 HIV 血清阴性和 99 名 HCV 血清阴性的 PWID。在 206 人年(PY)的随访期间,未报告 HIV 血清转换(HIV 发病率为 0/100PY,单侧 97.5%CI:0-1.8/100 PY)。报告了 18 例 HCV 血清转换,发病率为 19.4/100 PY(95%CI;11.5-30.7)。多变量分析显示,“每天注射两次以上”与 HCV 血清转换相关,调整后的优势比为 5.8(95%CI;1.8-18.1)。在海防,在展示艾滋病毒控制计划有效性的背景下,HCV 发病率仍然很高。应评估新的策略,如大规模获得 HCV 治疗,以解决 PWID 中的 HCV 传播问题。